Cann Group Limited has received a $315,552 advance on its expected FY2025 Research and Development Tax Incentive, marking the second tranche of funding to support its ongoing cannabis medicine development.
- Received $315,552 advance on FY2025 R&D Tax Incentive
- Second advance following initial $836,469 funding
- Total $1.15 million to be repaid from FY2025 R&D rebate
- Funds relate to R&D activities conducted March-April 2025
- Advance provided by Radium Capital under agreed terms
Cann Group Accelerates R&D Funding
Cann Group Limited (ASX – CAN), a leading developer of cannabis-based medicines, has announced it received a $315,552 advance on its anticipated Research and Development (R&D) Tax Incentive for the 2025 financial year. This latest advance follows an earlier tranche of $836,469, bringing the total funding accessed to $1,152,021.
The advance is provided by Radium Capital and relates to R&D activities conducted between March and April 2025. The funds are intended to support Cann Group’s ongoing research and development efforts, which are central to its strategy of innovating and supplying cannabis medicines to both Australian and international markets.
Strategic Use of R&D Tax Incentive Advances
Accessing R&D Tax Incentive advances is a common approach for companies like Cann Group to manage cash flow while continuing to invest in product development. The total borrowed amount of just over $1.15 million will be repaid from the Company’s R&D Tax Incentive rebate for FY2025, expected by 31 October 2025 or earlier if the rebate is received sooner.
This mechanism provides Cann Group with early access to funds tied to its innovation activities, allowing it to maintain momentum in its research programs without waiting for the formal rebate process to conclude. It also signals confidence in the company’s ability to deliver on its R&D commitments and secure the associated tax benefits.
Positioning for Growth in Cannabis Medicines
Cann Group operates state-of-the-art cultivation and manufacturing facilities in Victoria, Australia, including a large-scale GMP-certified site near Mildura. The company’s portfolio includes dried flower, oils, extracts, and pharmaceutical-grade cannabis medicines, with its proprietary Satipharm capsule technology enhancing product delivery and patient outcomes.
By leveraging R&D tax incentive advances, Cann Group is better positioned to accelerate innovation and expand its product offerings in a competitive and evolving market. The company’s ongoing investment in research underscores its commitment to enhancing patient lives through cannabis-based therapies.
Bottom Line?
Cann Group’s strategic use of R&D funding advances underscores its commitment to innovation and positions it well for upcoming milestones in FY2025.
Questions in the middle?
- When exactly will Cann Group receive the full R&D Tax Incentive rebate for FY2025?
- How will the advance funding impact Cann Group’s operational cash flow and investment plans?
- What specific R&D projects are being prioritized with this funding?